Citadel Advisors’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-59,403
| Closed | -$441K | – | 14351 |
|
|
2026
Q1 | $441K | Buy |
+59,403
| New | +$386K | ﹤0.01% | 9595 |
|
|
2025
Q4 | – | Sell |
-18,221
| Closed | -$71.1K | – | 13456 |
|
|
2025
Q3 | $71.1K | Buy |
+18,221
| New | +$74.7K | ﹤0.01% | 12031 |
|
|
2025
Q1 | – | Sell |
-16,870
| Closed | -$113K | – | 15093 |
|
|
2024
Q4 | $113K | Sell |
16,870
-7,676
| -31% | -$57.2K | ﹤0.01% | 11283 |
|
|
2024
Q3 | $190K | Sell |
24,546
-23,773
| -49% | -$143K | ﹤0.01% | 10233 |
|
|
2024
Q2 | $290K | Sell |
48,319
-2,637
| -5% | -$20K | ﹤0.01% | 9214 |
|
|
2024
Q1 | $459K | Buy |
50,956
+14,423
| +39% | +$131K | ﹤0.01% | 8583 |
|
|
2023
Q4 | $346K | Buy |
36,533
+20,308
| +125% | +$179K | ﹤0.01% | 8863 |
|
|
2023
Q3 | $193K | Sell |
16,225
-33,277
| -67% | -$590K | ﹤0.01% | 9978 |
|
|
2023
Q2 | $1.21M | Sell |
49,502
-47,100
| -49% | -$1.23M | ﹤0.01% | 6067 |
|
|
2023
Q1 | $3.02M | Buy |
96,602
+93,689
| +3,216% | +$5.42M | ﹤0.01% | 4616 |
|
|
2022
Q4 | $205K | Buy |
2,913
+1,388
| +91% | +$103K | ﹤0.01% | 10092 |
|
|
2022
Q3 | $131K | Sell |
1,525
-4,485
| -75% | -$436K | ﹤0.01% | 10847 |
|
|
2022
Q2 | $497K | Sell |
6,010
-18,879
| -76% | -$1.67M | ﹤0.01% | 8671 |
|
|
2022
Q1 | $4.14M | Buy |
24,889
+14,489
| +139% | +$2.08M | ﹤0.01% | 4542 |
|
|
2021
Q4 | $1.74M | Buy |
10,400
+6,277
| +152% | +$709K | ﹤0.01% | 6571 |
|
|
2021
Q3 | $356K | Buy |
4,123
+1,180
| +40% | +$78.1K | ﹤0.01% | 10683 |
|
|
2021
Q2 | $160K | Sell |
2,943
-207
| -7% | -$11.8K | ﹤0.01% | 12422 |
|
|
2021
Q1 | $188K | Buy |
3,150
+2,071
| +192% | +$121K | ﹤0.01% | 11777 |
|
|
2020
Q4 | $56K | Sell |
1,079
-336
| -24% | -$18.7K | ﹤0.01% | 10528 |
|
|
2020
Q3 | $68K | Sell |
1,415
-335
| -19% | -$16K | ﹤0.01% | 9476 |
|
|
2020
Q2 | $91K | Sell |
1,750
-90,653
| -98% | -$4.57M | ﹤0.01% | 9043 |
|
|
2020
Q1 | $4.03M | Buy |
92,403
+85,976
| +1,338% | +$3.5M | ﹤0.01% | 3009 |
|
|
2019
Q4 | $258K | Sell |
6,427
-220
| -3% | -$6.77K | ﹤0.01% | 7814 |
|
|
2019
Q3 | $218K | Buy |
6,647
+3,861
| +139% | +$186K | ﹤0.01% | 8043 |
|
|
2019
Q2 | $215K | Sell |
2,786
-1,539
| -36% | -$239K | ﹤0.01% | 8092 |
|
|
2019
Q1 | $768K | Buy |
+4,325
| New | +$852K | ﹤0.01% | 6063 |
|
Citadel Advisors's KZR Position: Q2 2026 in Review
Citadel Advisors sold out of Kezar Life Sciences (KZR) in Q2 2026, closing a stake of 59,403 shares — an estimated $441K sold.
Citadel Advisors first reported a position in KZR in Q1 2019 and held it in 26 quarters. The position peaked at $4.14M in Q1 2022. 0 funds tracked by Wall St. Rank hold KZR as of Q2 2026.
- Citadel Advisors reported no remaining Kezar Life Sciences position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 59,403 Kezar Life Sciences shares in Q2 2026, an estimated $441K.
- Citadel Advisors first reported a position in Kezar Life Sciences in Q1 2019 and held it in 26 quarters.
- Citadel Advisors's Kezar Life Sciences position peaked at $4.14M in Q1 2022.
- 0 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.